Skip to main navigation
Lisata Therapeutics Caladrius
Lisata Therapeutics Caladrius
  • Careers
  • Contact Us
  • Policies
BOLSTER Trial
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Advanced Solid Tumors Certepetide (LSTA1)
  • Research & Technology
    • Overview
    • CendR Platform® Technology – Targeted penetration technology to enhance drug delivery to advanced solid tumors
    • CD34+ Cell Technology
      • Coronary Microvascular Dysfunction (CMD) XOWNA®
      • Critical Limb Ischemia (CLI) LSTA12 (HONEDRA® in Japan)
      • Diabetic Kidney Disease (DKD) LSTA201
      • No-Option Refractory Disabling Angina (NORDA) LSTA14 (OLOGO™ in the USA)
      • CD34+ Cell Technology Publications
    • Publications
  • Investors & News
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
      • Media Coverage
    • Financials & Filings
      • Quarterly Results
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Corporate Governance
      • Docs & Charters
      • Management
      • Board of Directors
    • Historical Information
      • Historical Press Releases
      • Historical SEC Filings
    • Investor Resources
      • Stockholder Information
      • Investor FAQs
      • Email Alerts
      • IR Contact
      • Policies & Disclosures
  • Patients & Families
    • Overview
    • Cholangiocarcinoma (Bile Duct Cancer) Signs, Symptoms and Treatment
    • Metastatic Pancreatic Ductal Adenocarcinoma Symptoms, Signs & Treatment
  • Clinical Trials
Investors & News / RSS Feeds /

RSS Feeds

RSS (Really Simple Syndication) feeds provide an easy way to keep up with news and information about our company. Most web browsers have built in RSS readers, or you can use our feeds in an RSS reader or aggregator.

Latest Press Releases

Latest SEC Filings

Recent Events

  • Print Page
  • RSS Feeds
  • Email Alerts
Lisata Therapeutics Caladrius
Lisata Therapeutics Caladrius
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • Advanced Solid Tumors Certepetide (LSTA1)
  • Research & Technology
    • Overview
    • CendR Platform® Technology – Targeted penetration technology to enhance drug delivery to advanced solid tumors
    • CD34+ Cell Technology
    • Publications
  • Investors & News
    • Overview
    • News & Events
    • Financials & Filings
    • Stock Information
    • Corporate Governance
    • Historical Information
    • Investor Resources
  • Patients & Families
    • Overview
    • Cholangiocarcinoma (Bile Duct Cancer) Signs, Symptoms and Treatment
    • Metastatic Pancreatic Ductal Adenocarcinoma Symptoms, Signs & Treatment
  • Clinical Trials
  • Facebook
  • Twitter
  • LinkedIn
Join Our Email List

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100

© 2026 Lisata Therapeutics, Inc. All rights reserved.
  • Site Map
  • Privacy Policy

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100